ERBB2 and colorectal carcinoma: Analyzing both tissue and liquid biopsy samples, the authors illustrated the complex landscape of CRC molecular heterogeneity and detected HER2 amplification within the different and often co-occurrent mechanisms driving secondary resistance to EGFR blockade and converging on MAPK pathway reactivation [122].